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ABSTRACT
Introduction Investigating auditory functions in populations 
at risk of developing Alzheimer’s disease (AD) using auditory 
neurophysiological measurements can potentially identify 
a crucial and sensitive diagnostic window of opportunity in 
preclinical AD. Auditory electrophysiological assessments 
have gained interest as possible tools for early diagnosis 
of AD. This paper outlines the protocol that will be used 
to systematically review the published literature currently 
available on auditory electrophysiological assessments that 
have been used to assess the auditory functions of adults 
over the age of 60 years diagnosed with AD or its preclinical 
stages.
Methods and analysis All full- length peer- reviewed 
publications of original data that use auditory 
electrophysiological assessments in AD and its preclinical 
stages (subjective cognitive decline (SCD) and mild cognitive 
impairment (MCI)) will be considered in this review. The 
search will be performed on major electronic databases 
(Ovid MEDLINE, Ovid Embase, PsycINFO, PubMed, Scopus 
and CINAHL Plus) using keywords alone or in combination 
with Medical Subject Headings divided into two domains; 
(i) auditory tests and (ii) AD. The database search will 
be conducted on the 7th of May 2019. Data analysis will 
be completed and reported in the full review. A random 
effects meta- analysis will also be conducted using the 
Comprehensive Meta- Analysis software, V.3. This review 
will describe which auditory electrophysiological tests 
have been found to be useful in assessing the auditory 
function in cognitively impaired adults (MCI and AD) or 
adults with serious complaints about their cognition (SCD). 
This review will also identify and describe which auditory 
electrophysiological test demonstrates the most sensitivity 
in differentiating people at different stages of cognitive 
decline.
Ethics and dissemination This systematic review focusses 
on analysing already available literature. Therefore, there 
will be no requirement for ethical approval. The systematic 
review findings will be disseminated through peer- reviewed 
publication as well as relevant media platforms, for example, 
conferences.
Systematic review registration PROSPERO 
CRD42019133553.
INTRODUCTION
Worldwide, someone develops dementia 
every 3 seconds, and in 2017 the number of 
people estimated to be living with dementia 
globally was close to 50 million people.1 
Without a medical breakthrough the number 
of dementia cases is expected to double 
every 20 years, with it estimated to be over 
152 million cases by 2050.2 Contributing to a 
total of 5.4% of deaths in males and 10.6% of 
deaths in females each year, dementia is the 
second leading cause of death of Australians.3 
Everyday approximately 250 Australians are 
diagnosed with dementia, and this number is 
expected to increase to 650 people a day by 
2056.1
Dementia of the Alzheimer’s disease (AD) 
type accounts for 60% to 80% of all dementia 
cases.4 It is characterised by loss of episodic 
memory as well as loss of other cognitive func-
tions.5 Cognitive decline has been shown to be 
strongly associated with hearing loss with the 
probability of incident dementia log- linearly 
increasing with the severity of hearing loss.6 
Strengths and limitations of this study
 ► This systematic review protocol follows the Preferred 
Reporting Items for Systematic Review and Meta- 
Analysis Protocols (PRISMA- P) guidelines.
 ► This protocol outlines the procedure for a systematic 
review which will reduce the possibility of duplica-
tion of the methods and allows for peer review of 
the procedure.
 ► This will offer highest level evidence for informed 
decisions.
 ► The detailed keyword and Medical Subject Headings 
term search methods offer a more comprehensive 
search of relevant publications.
 ► The exclusion of papers that are not published in 
English may mean some important additional find-
ings are not taken into consideration.
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In addition, results from a number of longitudinal studies 
suggest that changes in central auditory processing skills, 
even in the absence of severe peripheral hearing loss, 
are associated with high incidence of cognitive decline 
and AD.7 8 Changes in the human auditory system can 
be objectively measured which can provide an avenue in 
differentiating normal age- related cognitive dysfunction 
from AD and its prodromal states.9–11
Investigating peripheral and central auditory functions 
in populations at risk of developing AD using auditory 
neurophysiological measurements combined with audio-
logical assessments can potentially identify a crucial and 
sensitive diagnostic window of opportunity in preclin-
ical AD. Auditory electrophysiological assessments have 
gained interest as possible tools for early diagnosis of AD. 
The present paper outlines the protocol used to systemati-
cally review the published literature currently available on 
auditory electrophysiological assessments that have been 
used to assess the auditory functions of adults over the age 
of 65 years diagnosed with AD and its preclinical stages 
including those with mild cognitive impairment (MCI) 
and subjective cognitive decline (SCD). The aims of the 
systematic review and meta- analysis are; (i) to determine 
the magnitude of auditory electrophysiological compo-
nent amplitude and/or latency abnormalities present in 
AD, MCI and SCD when compared with controls, (ii) to 
determine which auditory electrophysiological compo-
nent can be used to differentiate between the different 
study groups (ie, AD, MCI, SCD and controls) and (iii) 
to determine which auditory electrophysiological assess-
ments can yield a possible diagnostic tool for preclinical 
AD.
METHODS
This systematic review will follow the Preferred Reporting 
Items for Systematic Review and Meta- Analysis (PRISMA) 
statement.12 This protocol is reported in accordance 
with the PRISMA- Protocols (PRISMA- P) 2015 checklist.13 
This systematic review is registered in the PROSPERO; 
International Prospective Register of Systematic Reviews, 
(http://www. crd. york. ac. uk/ PROSPERO/).
Eligibility criteria
All full- length peer- reviewed publications of original data 
related to auditory electrophysiological assessments in AD 
or its preclinical stages available on the selected databases 
published between 1985 and May 2019 will be considered 
in this review.
The eligibility criteria (table 1) illustrate the inclusion 
and exclusion criteria for publications based on four cate-
gories; publication type, population type, assessment type 
and reported outcome. Only publications of original data 
that are reported in English will be included in this review, 
publication of non- original data such as reviews or edito-
rials will not be included in this review. In order to be 
included in this review all studies must have one or more 
subject groups with cognitive impairment associated with 
AD and its preclinical stages. The studies must also have 
used auditory electrophysiological assessments either as a 
tool for assessing hearing abilities in cognitively impaired 
adults or as a diagnostic tool for cognitive impairment. 
Studies using a non- human subject pool and subject 
groups under the age of 60 will be excluded from this 
review. The full inclusion and exclusion criteria is illus-
trated in table 1.
Information sources
The search will be conducted on the following major data-
bases in medicine, neuroscience and psychology: Ovid 
Embase, Ovid MEDLINE, PsycINFO, PubMed, Scopus 
and CINAHL Plus. A hand search of references and cita-
tions of the included publications will also be conducted 
using Google Scholar. In addition, a grey literature search 
will be conducted using Google Scholar to identify any 
relevant studies that would not be found through the 
major database searches.
Search strategy
Medical Subject Headings (MeSH) in exploded mode in 
conjunction with keyword searches will be used to maxi-
mise the sensitivity of the search strategy in the Embase, 
MEDLINE and PsycINFO databases. Keyword searches 
with synonyms, abbreviations, truncations and different 
spellings (see table 2) will also be used in the PubMed, 
Scopus and CINAHL Plus databases. The search terms 
are divided in two domains; (i) auditory tests and (ii) 
Alzheimer’s disease, refer to table 2.
Data management and study selection
All results from database and hand searches will be 
exported into EndNote X7 software (Thomson Reuters, 
2016), where the duplicate publications will be removed. 
The study selection will then be undertaken in two stages; 
first, the titles and abstracts will be screened against the 
eligibility criteria to confirm whether they are suitable 
for the final review; second, the full- texts for the eligible 
publications will be analysed against the eligibility criteria. 
The search strategy and publication screening will be 
conducted by two authors (HYT and DMPJ) assisted by 
Covidence,14 a systematic review publication organisa-
tional tool (http://www. covidence. org). Any discrepan-
cies between the two authors where a consensus could 
not be reached will be resolved through discussion and 
consultation with a third reviewer (WHAMM).
Data items and collection process
Data extracted from publications for this review will 
include the following:
1. Publication characteristics: authors, year of publica-
tion, journal of publication, title, study objective, study 
design.
2. Participant characteristics: geographical location of the 
study, number of participants, age of subject groups, 
diagnosis method of the disease (SCD or MCI or AD), 
Mini- Mental State Examination score (if reported).
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3. Assessment characteristics: testing methods applied, 
for example, auditory electrophysiology assessment 
task/paradigm.
4. Outcome characteristics: which auditory electrophys-
iological measures were used, major findings on com-
ponents latency and/or amplitude, major conclusions 
and limitations or difficulties of testing procedures.
The data extracted will be analysed qualitatively to 
identify any particular patterns, similarities or differences 
between studies. The data extracted from the publica-
tions will provide information about any gaps in knowl-
edge and the future direction of research on auditory 
electrophysiology in AD and its preclinical stages.
Quality assessment
All articles will be assessed to address the risk of; selec-
tion bias, performance bias, analysis bias and reporting 
bias. A quality assessment tool developed by Thomas et 
al15 will be used to evaluate the methodological quality of 
the quantitative studies included in the systematic review. 
The quality assessment findings will be analysed, and the 
evidence will be tabulated in order to grade the recom-
mendations based on the American Society of Plastic 
Surgeons’ Evidence Rating Scale for Therapeutic Studies 
scale for grading recommendations.
Meta-analytic approach
The meta- analysis will be conducted using the Compre-
hensive Meta- Analysis (V.3) software developed by 
Biostat.16 The data in each study will be refined for the 
meta- analysis; (1) grand averages of multiple electrode 
site measures will be pooled into a single mean for each 
group, (2) measures reported in subgroups (eg, male 
and female separately) will be pooled and analysed as a 
single group, (3) event- related potential (ERP) compo-
nents reported as subcomponents (eg, P300 as P3a and 
Table 1 Eligibility criteria
Eligibility criteria Include Exclude
Publication type  ► Peer- reviewed, full- length publications of original data.  ► Non- original data publications; editorials, 
reviews, letters, opinion pieces, 
miscellaneous reports, non- empirical 
studies.
 ► Publications written in English.  ► Publications in any language other than 
English.
 ► All articles on the topic published between 1985 and May 
2019.
Population type  ► Studies that include participants with dementia of the 
Alzheimer’s type and/or its prodromal states.
 ► Studies that only address non- cognitively 
impaired adults or adults without memory 
complaints.
 ► Studies with participants that are healthy and participants with 
cognitive impairment or memory complaints if the data for 
cognitively impaired participants is reported.
 ► Studies with no age matched comparison 
(control) group.
 ► Studies conducted on humans only.  ► Studies on children or adults with the mean 
age under 60.
 ► Studies conducted on humans and other animals if data for 
humans is reported.
 ► Studies with an age matched comparison (control) group.
 ► Studies on elderly adult participants; mean age of 60 years 
old or older (If mean age not specified the age range for the 
subject must start at 60 years old).
Assessment type  ► Studies that use auditory electrophysiological assessments 
either as a tool for assessing hearing abilities in cognitively 
impaired adults or as a diagnostic tool for cognitive 
impairment.
 ► Studies that only use auditory assessments 
that are not electrophysiological.
 ► Studies that use a recognised diagnostic criteria, 
neuropsychological evaluation or medical imaging to 
diagnose/classify the AD or MCI groups.
 ► Non- human studies.
 ► Studies that use non- auditory electrophysiological 
assessments as well as auditory electrophysiological 
assessments, if the data for the auditory electrophysiological 
assessments is reported.
Reported outcome  ► Latency and amplitude measures of the auditory 
electrophysiological assessments.
 ► Self- reported outcomes.
AD, Alzheimer’s disease; MCI, mild cognitive impairment.
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P3b) will be combined as a single mean for each group 
and (4) only baseline measures of the ERP components 
will be included in the meta- analysis. Standard difference 
in mean with 95% CIs will be reported as synthesised 
measure of effect size. The standard mean difference 
reflects the difference between the means of two groups 
divided by their pooled SD. The data for the meta- analysis 
will be entered as continuous outcomes under the random 
effects model. The random effects model will be used to 
account for variation between study methodologies. The 
q- value statistic will be performed to test heterogeneity of 
the studies and the I² statistic will indicate heterogeneity 
as a percentage. A p value <0.05 will be considered statisti-
cally significant for all analyses.
Synthesis of results
The data extracted from the studies will be tabulated to 
illustrate the overall methodological quality, the main 
findings, the main conclusions and the level of evidence 
for each study. The findings will be analysed based on 
the patient group (SCD, MCI or AD) and the clinical 
testing approach (type of auditory electrophysiological 
assessment and type of outcome measures) in order to 
synthesise the evidence. An understanding of the feasi-
bility, efficiency, effectiveness and quality of the use of 
each auditory electrophysiological assessment in the 
patient groups will be developed through the synthesis 
of the results.
Patient and public involvement
Patient and public involvement is not required for this 
systematic review.
ETHICS AND DISSEMINATION
The aim of this review is to investigate and describe the 
different auditory electrophysiological tests that have 
been used in clinical studies in participants with SCD, 
MCI and AD. This review will provide information about 
which auditory electrophysiological tests have been found 
to be useful in assessing auditory function in cognitively 
impaired adults. Additionally, the review will identify the 
strengths and limitations of each auditory electrophysio-
logical test and identify which auditory electrophysiolog-
ical test demonstrates most sensitivity in differentiating 
subject groups; that is, between those at different stages 
Table 2 Keywords and Medical Subject Headings (MeSH) terms (explode) applied per domain in search databases
Domain Keywords MeSH terms
Auditory tests psychoacoustic test* OR auditory test OR central auditory test 
OR electrophysiological assessment OR electrophysiology OR 
electroencephalography OR ECochG OR ECOG OR event related 
potential OR ERP OR AEP OR evoked auditory response OR acoustic* 
evoked response OR acoustic* evoked potential OR auditory event 
related potential OR AERP OR auditory brainstem response OR ABR 
OR auditory brainstem responses OR ABRs OR speech- evoked ABR 
OR complex ABR OR cABR OR brainstem auditory evoked potential 
OR frequency following response OR FFR OR frequency following 
potential OR FFP OR envelope following response OR EFR OR auditory 
middle latency response OR AMLR OR auditory MLR OR middle latency 
response OR middle- latency response OR MLR OR middle latency 
responses OR MLRs OR transient middle latency response OR middle 
latency auditory evoked potentials OR MLPs OR Na OR Pa OR Nb 
OR Pb OR slow vertex potential OR slow- vertex potential OR SVP OR 
slow vertex response OR SVR OR V potential OR late cortical response 
OR long latency auditory evoked potential OR cortical event- related 
potentials OR P1 OR P100 OR N1 OR N100 OR P2 OR P200 OR N2 
OR N200 OR P50 OR late positive component OR late positive complex 
OR LPC OR late latency response OR LLR OR slow latency auditory 
evoked potentials OR SLAEPs OR late latency auditory evoked potentials 
OR LLAEPs OR P300 OR P3 OR mismatched negativity OR MMN OR 
mismatched field OR MMF OR contingent negative variation OR CNV 
OR N4 OR N400 OR P6 OR P600 OR auditory steady- state response 
OR ASSR OR multiple auditory steady- state response OR MASTER OR 
multiple- frequency ASSR OR multiple- ASSR OR steady state evoked 
response OR SSER OR Steady state evoked potential OR SSEP OR 
4 kHz response
Hearing tests OR Auditory evoked 
potentials OR Audiometry
Alzheimer’s disease Alzheimer* disease OR Alzheimer* OR Dementia OR AD OR cognitive 
impairment OR cognitive decline OR cognitive processing OR cognitive 
ability dementia OR Alzheimer* type dementia OR mild cognitive 
impairment OR MCI OR amnestic MCI OR amnestic mild cognitive 
impairment OR minimal cognitive impairment OR moderate cognitive 
impairment OR severe cognitive impairment OR subjective memory 
complainers OR SMC OR subjective cognitive decline OR SCD
Dementia OR Cognitive 
dysfunction, impairment OR 
Cognition disorders
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of cognitive impairment. This review will also contribute 
to the study design of clinical studies looking at auditory 
evoked potentials in patients with AD and its preclinical 
stages. The full review and meta- analysis will be submitted 
for publication in a peer- reviewed journal and the results 
will be presented at conferences and meetings relevant to 
the field. Ethical approval is not required as no primary 
data will be collected.
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